Reply

Jaclyn LoPiccolo, Michael I. Brener, Kiyoko Oshima, Evan J. Lipson, James P. Hamilton – 28 February 2019

Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Steven M. Kawut, Susan S. Ellenberg, Michael J. Krowka, David Goldberg, Hugo Vargas, David Koch, Tiffany Sharkoski, Nadine Al‐Naamani, Alyson Fox, Robert Brown, Joshua Levitsky, Jae K. Oh, Grace Lin, Nianfu Song, Carl Mottram, Margaret F. Doyle, David E. Kaplan, Samir Gupta, Michael B. Fallon – 28 February 2019 – The tyrosine kinase inhibitor sorafenib improves hepatopulmonary syndrome (HPS) in an experimental model. However, the efficacy and adverse effect profile in patients with HPS are unknown.

Subscribe to